2012-09-18 07:54:18 - Recently published research from Global Markets Direct, "Eosinophilic Esophagitis - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Eosinophilic Esophagitis - Pipeline Review, H2 2012', provides an overview of the Eosinophilic Esophagitis therapeutic pipeline. This report provides information on the therapeutic development for Eosinophilic Esophagitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis. 'Eosinophilic Esophagitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the

indicated disease.

Scope


Full Report Details at
- www.fastmr.com/prod/463756_eosinophilic_esophagitis_pipeline_rev ..


* A snapshot of the global therapeutic scenario for Eosinophilic Esophagitis.
* A review of the Eosinophilic Esophagitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Eosinophilic Esophagitis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Eosinophilic Esophagitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Eosinophilic Esophagitis pipeline depth and focus of Eosinophilic Esophagitis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Eosinophilic Esophagitis Therapeutic Products under Development, Key Players in Eosinophilic Esophagitis Therapeutics, Eosinophilic Esophagitis Pipeline Overview, Eosinophilic Esophagitis Pipeline, Eosinophilic Esophagitis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Eosinophilic Esophagitis Overview
An Overview of Pipeline Products for Eosinophilic Esophagitis
Eosinophilic Esophagitis Therapeutics under Development by Companies
Eosinophilic Esophagitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Eosinophilic Esophagitis Therapeutics - Products under Development by Companies
Eosinophilic Esophagitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Eosinophilic Esophagitis Therapeutics Development
Novartis AG
Axcan Pharma Inc.
Cephalon, Inc.
Meritage Pharma, Inc.
Oxagen Limited
Eosinophilic Esophagitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Cinquil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OC000459 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oral Viscous Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QAX-576 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Montelukast - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluticasone Propionate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluticasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Omalizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EUR-1100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Eosinophilic Esophagitis Therapeutics - Drug Profile Updates
Eosinophilic Esophagitis Therapeutics - Dormant Products
Eosinophilic Esophagitis - Product Development Milestones
Featured News & Press Releases
Aug 13, 2012: Meritage Initiates Clinical Trial Of Oral Budesonide Suspension For Adolescent And Adult Patients With Eosinophilic Esophagitis

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=463756&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.